| プロジェクト | 薬物タイプ | 治療分野 | 適応症 | ステージ | エリア |
|---|---|---|---|---|---|
| Anti-GCC humanized antibody | Bispecific antibody | Oncology/Cancer | Solid Tumor | Preclinical | Global |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|
| anti-GUCY2C CAR T-cell therapy (Parasol Biotechnology/Anhui provincial cancer hospital) | Phase 1 Clinical | HeFei Parasol Biotech Co Ltd | Colorectal Neoplasms | 詳細 | |
| anti-guanylyl cyclase C CAR-T cell therapy (Legend Biotech) | LCAR-G08T | Phase 1 Clinical | Legend Biotech Corp | Colorectal Neoplasms; Gastrointestinal Neoplasms | 詳細 |
| HD-006 | HD006; HD-006 | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Solid tumours | 詳細 |
| REVO-UWD-01 | REVO-UWD-01; WD 01 | Phase 1 Clinical | Wondercel Therapeutics Co Ltd | Colorectal Neoplasms | 詳細 |
| IM96 CAR-T cell Therapy | IM96 | Phase 1 Clinical | Imunopharm Technology Co Ltd | Colorectal Neoplasms; Digestive System Neoplasms; Esophageal Neoplasms; Gastroesophageal Junction Neoplasms; Pancreatic Neoplasms; Solid tumours; Stomach Neoplasms | 詳細 |
| GCC19CART | GCC19CART; LYL273; LYL-273 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Colorectal Neoplasms; Rectal Neoplasms | 詳細 |
| Gucy2c cart cell therapy (Innovative Cellular Therapeutics) | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Digestive System Neoplasms | 詳細 | |
| XKDCT-080 | XKDCT-080 | Clinical | The Affiliated Hospital Of Qingdao University | Colonic Neoplasms; Solid tumours | 詳細 |
| CT-080 | CT-080 | Clinical | Shenzhen Celconta Life Science Co Ltd | Solid tumours | 詳細 |
| 英語名 | 研究コード | 研究開発ステージ | 会社 | オリジナル製品名 | 最初に承認をした国 | 最初の適応症 | 最初に承認を受けた会社 | 承認された日付 | 適応症 | 臨床試験 |
|---|---|---|---|---|---|---|---|---|---|---|
| Plecanatide | SP-304; GCRA | Approved | Synergy Pharmaceuticals Inc | Trulance | United States | Constipation; Chronic idiopathic constipation | Salix Pharmaceuticals | 2017-01-19 | Chronic idiopathic constipation; Constipation; Irritable Bowel Syndrome | 詳細 |